Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Bowel Disorders: Introduction

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

Acute Pancreatitis II: Clinical Manifestations and Management

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

The New England journal of medicine·2026

Same author

Choice of oncologist and influencing factors: analysis of the Pancreatic Cancer Action Network registry.

The oncologist·2025

Same author

Protected Time, Resources, and Expectations for Academic Oncology Clinical Research Physicians.

Journal of the National Comprehensive Cancer Network : JNCCN·2025

Same author

Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study.

Journal of the National Comprehensive Cancer Network : JNCCN·2024

Same author

The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.

JCO precision oncology·2023

Same author

Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.

Journal of the National Cancer Institute·2023

Search research articles

Related Experiment Video

Updated: May 3, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

Advanced biliary tract cancers.

Laura Williams Goff¹, Jordan D Berlin¹

¹From the Vanderbilt Ingram Cancer Center, Nashville, TN.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting

|January 24, 2014

Summary

This summary is machine-generated.

Metastatic biliary tract cancers have limited treatment options. Gemcitabine plus cisplatin improved survival, establishing a new standard of care, while targeted therapies show promise.

More Related Videos

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

Laparoscopic Common Bile Duct Exploration in Patients with a Previous History of Biliary Tract Surgery

Laparoscopic Common Bile Duct Exploration in Patients with a Previous History of Biliary Tract Surgery

Published on: February 10, 2023

Related Experiment Videos

Last Updated: May 3, 2026

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

Laparoscopic Common Bile Duct Exploration in Patients with a Previous History of Biliary Tract Surgery

Laparoscopic Common Bile Duct Exploration in Patients with a Previous History of Biliary Tract Surgery

Published on: February 10, 2023

Area of Science:

Medical Oncology
Gastroenterology
Cancer Research

Background:

Single-agent chemotherapy with 5-fluorouracil or gemcitabine offers limited efficacy in metastatic biliary tract cancers.
Phase II trial analysis suggests platinum agents enhance fluoropyrimidine effectiveness.
Best supportive care alone is less effective than 5-fluorouracil.

Purpose of the Study:

To review current and emerging systemic therapies for metastatic biliary tract cancers.
To discuss established and novel standards of care.
To highlight the role of targeted agents in treatment strategies.

Main Methods:

Review of phase II and III clinical trials.
Analysis of data on single-agent and combination chemotherapy regimens.
Evaluation of preliminary evidence for targeted therapies, including epidermal growth factor receptor inhibitors.

Main Results:

Gemcitabine plus cisplatin significantly improved overall survival and progression-free survival compared to gemcitabine alone in a phase III trial.
This combination has become a new standard of care for metastatic biliary tract cancers.
Epidermal growth factor receptor inhibitors demonstrate preliminary activity in biliary tract cancer management.

Conclusions:

The gemcitabine/cisplatin combination represents a significant advancement in metastatic biliary tract cancer treatment.
Future research should focus on novel targeted agents for improved patient outcomes.
Systemic therapy continues to evolve, offering new hope for patients with advanced disease.